- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01305850
The Effect of Aliskiren and Losartan on Peritoneal Membrane in Continuous Ambulatory Peritoneal Dialysis Patients
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Detailed description:
Many peritoneal dialysis patients suffer from uremia due to inadequate dialysis or volume overload caused by failure of peritoneal membrane transportation. One of the most important etiologies of peritoneal membrane failure is unavoidable to use high glucose-containing dialysate solution that induces injury to mesothelial cells. Previous data found that injured mesothelial cell produced Angiotensin II inducing peritoneal inflammation and fibrosis. Blockade of the renin-angiotensin system by angiotensin-converting enzyme inhibition or angiotensin receptor antagonism play a major role to slow these effects.
Many trials in animal studies have proved the benefit of angiotensin-converting enzyme inhibition and angiotensin receptor antagonism in preservation of peritoneal membrane but clinical evidences in human are controversy in the past. Recently our data have demonstrated the roles of angiotensin-converting enzyme inhibition and angiotensin receptor antagonism for slowing peritoneal membrane dysfunction in views of anatomy and solute transportation (abstract presentation in American Society of Nephrology 2010). These available data confirmed that renin-angiotensin system blockages were benefit. Nowadays, there is a new class of antihypertensive drug, called direct renin inhibitor . It blocks (pro)renin active site that is the rate- limiting step of renin-angiotensin system. We're interesting in this drug and wonder it can slow the peritoneal membrane dysfunction in continuous ambulatory peritoneal dialysis patients. Therefore, we design a study to show the effect of aliskiren alone or combination with angiotensin receptor antagonism for slowing peritoneal membrane dysfunction in naive continuous ambulatory peritoneal dialysis patients in several hospitals. Our study will be taken in 1 year duration and uses modified peritoneal equilibrium test and dialysate cancer antigen 125 (CA125) as indexes of peritoneal membrane transportations.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Talerngsak Kanjanabuch, Assist. Prf.
- Phone Number: 211 662-2564321
- Email: golfnephro@hotmail.com
Study Locations
-
-
-
Bangkok, Thailand, 10330
- Recruiting
- Chulalongkorn University
-
Principal Investigator:
- Talerngsak Kanjanabuch, Assist. Prf.
-
Contact:
- Talerngsak Kanjanabuch, Assist. Prf.
- Phone Number: 211 662-2564321
- Email: golfnephro@hotmail.com
-
Sub-Investigator:
- Pichaya Tantiyavarong, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- All patients received continuous ambulatory peritoneal dialysis less than one and a half years
- Subjects of either sex, more than 20 years old
- Hypertension
- Provision of written informed consent by subject or guardian
Exclusion Criteria:
- No history of taking an angiotensin converting enzyme inhibitor or angiotensin-receptor blockers or aldosterone antagonist for at least 2 month
- Serum potassium more than 5.5 mEq/L
- History of renal artery stenosis
- Peritonitis or volume overload within the preceding 1 month
- Myocardial infarction within the preceding 6 months or clinically significant valvular disease or any active cardiovascular disease
- History of malignant hypertension or hypertensive encephalopathy or cerebrovascular accident within the preceding 6 months
- Any condition that may have precluded a patient from remaining in the study, such as alcohol or drug abuse, chronic liver disease, malignant disease, or psychiatric disorder
- History of allergy or intolerance to an angiotensin converting enzyme inhibitors or angiotensin receptor blockers
- Hypotension defined as systolic blood pressure less than 90 mmHg
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: placebo
|
Patients in the control group will administer antihypertensive agents, except angiotensin converting enzyme inhibitors, angiotensin receptor blockers and spironolactone.
Dosages are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
Other Names:
|
Active Comparator: Aliskiren
|
Patients with hypertension will take fixed-dose 150 mg aliskiren per day.
Antihypertensive agents other than angiotensin converting enzyme inhibitors, angiotensin receptor blocker and spironolactone will be allowed and dosages are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
Other Names:
|
Active Comparator: Enalapril plus Losartan
|
Patients with hypertension will take fixed-dose 20 mg enalapril + 50 mg losartan per day.
Antihypertensive agents other than angiotensin converting enzyme inhibitors, angiotensin receptor blockers and spironolactone will be allowed and dosages are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
Other Names:
|
Active Comparator: Aliskiren plus Losartan
|
Patients with hypertension will take fixed-dose 150 mg aliskiren + 50 mg losartan per day.
Antihypertensive agents other than angiotensin converting enzyme inhibitors, angiotensin receptor blockers and spironolactone will be allowed and dosages are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changing in modified peritoneal equilibrium test
Time Frame: at the beginning, 6 months and 12 months
|
Modified peritoneal equilibrium test is the standard test for evaluation peritoneal membrane transportation.
|
at the beginning, 6 months and 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
appearance rate of dialysate CA125
Time Frame: the begining, 6 months and 12 months
|
Appearance rate of dialysate CA125 refers to anatomical change of peritoneal.
It can be calculated by multiplying dialysate CA125 with dialysate volume and deviding by dwell time.
|
the begining, 6 months and 12 months
|
nutritional status
Time Frame: at the beginning, 6 months and 12 months
|
assess by serum albumin and subjective global assessment
|
at the beginning, 6 months and 12 months
|
adverse events
Time Frame: 12 months
|
adverse events of the drugs
|
12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Talerngsak Kanjanabuch, Assist. Prf., Investigator
- Study Director: Pichaya Tantiyavarong, MD., Chulalongkorn University
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 162/53
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Peritoneal Membrane Failure
-
Heidelberg UniversityCompletedChronic Renal Failure | Peritoneal Membrane DisorderAustria, Finland, France, Germany, Italy
-
Sunnybrook Health Sciences CentreNot yet recruitingPeritoneal Dialysis Complication | Peritoneal Dialysis Access FailureCanada
-
Air Force Military Medical University, ChinaNot yet recruitingPeritoneal Dialysis Access Failure
-
Turku University HospitalKarolinska Institutet; IRCCS Azienda Ospedaliero-Universitaria di Bologna; Medical... and other collaboratorsUnknownExtracorporeal Membrane Oxygenation | Cardiac Surgery | Acute Heart Failure | Cardiac Output, Low | Low Output Heart Failure | Venoarterial Extracorporeal Membrane OxygenationFinland
-
An-Najah National UniversityCompletedPeritoneal Dialysis Complication | Ultrafiltration FailurePalestinian Territory, occupied
-
Nationwide Children's HospitalAmerican Heart AssociationCompletedExtracorporeal Membrane Oxygenation Complication | Cardiac FailureUnited States
-
Academisch Medisch Centrum - Universiteit van Amsterdam...RecruitingExtracorporeal Membrane Oxygenation Complication | Cerebral Circulatory FailureNetherlands
-
Erasmus Medical CenterRecruitingExtracorporeal Membrane Oxygenation | Cardio/Pulm: Heart FailureNetherlands
-
Boston Children's HospitalRecruitingExtracorporeal Membrane Oxygenation | Red Blood Cell Transfusion | Organ Failure, MultipleUnited States, Canada
-
University Hospital Birmingham NHS Foundation TrustCompletedPeritoneal Dialysis | Chronic Renal Failure | End Stage Renal Failure | Continuous Ambulatory Peritoneal DialysisUnited Kingdom
Clinical Trials on Aliskiren
-
NovartisCompletedHypertensionSlovakia, Italy, Netherlands, Argentina, Germany, Poland, Czech Republic, Iceland
-
NovartisCompletedEssential HypertensionGermany, Spain, United States
-
Novartis PharmaceuticalsCompletedHypertensionUnited States, Belgium, Hungary, Turkey, Guatemala, Slovakia, Germany, Puerto Rico, Poland
-
Novartis PharmaceuticalsCompleted
-
NovartisCompleted
-
University of Campania "Luigi Vanvitelli"IRCCS San RaffaeleUnknownHypertension | End Stage Renal Disease
-
NovartisCompletedHypertensionUnited States
-
NovartisCompleted
-
NovartisCompletedHypertensionUnited States, Germany
-
Taipei Veterans General Hospital, TaiwanNational Taiwan University HospitalUnknown